After lengthy negotiations, Bayer has reached a deal with union representatives that will result in a sizeable reduction in managerial roles, part of a cost-cutting drive
One of Germany’s main trade unions has pushed back against any future break-up of pharmaceutical and agrochemicals giant Bayer, claiming such a move would put thousands of
Bayer’s AskBio gene therapy unit has started recruiting patients into a phase 2 trial of its AB-1002 candidate for congestive heart failure (CHF), buoyed by encouraging da
New data for Astellas Pharma’s non-hormonal menopause therapy fezolinetant has shown it remains effective to 24 weeks, consolidating the evidence of the drug as it starts
Bayer has decided to discontinue a phase 3 trial of its oral Factor XIa inhibitor asundexian in patients with atrial fibrillation (AF), after an interim analysis concluded
Bayer has said it plans to withdraw its PI3K inhibitor Aliqopa from the US market as a treatment for follicular lymphoma (FL) after the drug failed a confirmatory trial, d
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.